Sign up
Pharma Capital

CytoDyn to meet with FDA to finalize next steps on leronlimab drug trial for HIV

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors the FDA has requested an in-person meeting to discuss and potentially finalize the biotechnology company’s protocol for a trial of flagship drug leronlimab as a single treatment for HIV patients.

Dr Pourhassan also addresses the company's stagnant share price, and whether this poses a risk.


View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.